Sun Pharma Advanced Research Company Ltd. has submitted its Monitoring Agency Report for the quarter ended September 30, 2026. The report, issued by Acuité Ratings and Research Limited, confirms that the utilization of proceeds from the preferential issue of warrants has been in line with the disclosed objects. There have been no deviations observed in the application of funds, ensuring transparency and accountability to stakeholders.
Monitoring Agency Report for Q3 FY27 Filed
Sun Pharma Advanced Research Company Ltd. has formally submitted its Monitoring Agency Report concerning the utilization of funds raised through a recent preferential issue of warrants. This report covers the financial quarter ending September 30, 2026.
Key Findings from the Report
The independent Monitoring Agency, Acuité Ratings and Research Limited, has affirmed that the company’s utilization of the preferential issue proceeds aligns with the objectives outlined in the offer document. Specifically, the report states that there has been ‘No deviation is observed’ in the application of these funds. This finding signifies that the proceeds have been used as intended, adhering to regulatory requirements and investor expectations.
Financial Commitments and Utilization
The total issue size for the preferential issue was INR 599.98 crore. The funds were allocated towards specific objects, including part repayment of outstanding working capital loans (INR 150.00 crore), research and development activities including clinical trials (INR 300.00 crore), and general corporate purposes (INR 149.98 crore). The report indicates that funds allocated for the repayment of working capital loans were fully utilized in the first quarter of FY 2026-27. For research and development activities, no additional warrants were subscribed during the review quarter, consequently leading to no additional proceeds being received. This resulted in no funds being available for utilization against these stated objects during the quarter.
Compliance and Oversight
The report was prepared in accordance with the format prescribed by SEBI. It was reviewed by the Audit Committee and the Board of Directors of Sun Pharma Advanced Research Company Ltd., confirming the adherence to established financial practices and disclosures. The report ensures that the company maintains transparency in its financial dealings and the strategic deployment of capital.
Source: BSE
